Navigation Links
Sinovac to Participate at 2010 Shanghai CPhI Exhibition
Date:5/26/2010

BEIJING, May 26 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading China-based vaccine manufacturer, announced today that the Company will participate at the 2010 Shanghai CPhI Exhibition, being held June 2-4, 2010. Sinovac's exhibition booth will be located in Hall E4, No. E4C42. At the exhibition, Sinovac will showcase its commercialized products, including its Healive, Anflu, Panflu and Panflu.1 vaccines.

Mr. Weidong Yin, Chairman, President and CEO of Sinovac, remarked, "We are excited to participate in the CPhI Exhibition in Shanghai, where we will feature our high quality products, such as vaccines against hepatitis A and seasonal influenza. As the exhibition attracts a global audience, we look forward to meeting with current and potential new international distribution partners to explore opportunities to further advance our global distribution strategy."

The Shanghai CPhI Exhibition provides Sinovac and other exhibitors/attendees with the opportunity to gain a better understanding of the global pharmaceutical industry. In 2009, a total of 1,651 exhibitors attended the event, including 127 overseas companies from 16 countries and regions. In addition to the exhibition booths, CPhI also hosted 54 high level conferences and seminars during the event, providing exhibitors and attendees with the opportunity to further communicate and exchange the latest information in the pharmaceutical industry.

About Sinovac

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases. Sinovac's vaccine products include Healive(R) (hepatitis A), Bilive(R) (combined hepatitis A and B), and Anflu(R) (influenza). Panflu(TM), Sinovac's pandemic influenza vaccine (H5N1), has already been approved for government stockpiling. Sinovac is developing vaccines for enterovirus 71, universal pandemic influenza, Japanese encephalitis, and human rabies. Its wholly owned subsidiary, Tangshan Yian, is conducting field trials for independently developed inactivated animal rabies vaccines. Its 30%-owned joint venture, Sinovac Dalian, focuses on the research, development, manufacturing and commercialization of vaccines, such as rabies, chickenpox, mumps and rubella vaccines for human use.

About CPhI Worldwide

CPhI Worldwide was launched in 1990 as an international convention on pharmaceutical ingredients and intermediates. This inaugural CPhI attracted 250 visitors for the 16 exhibitors. Today this has grown to an unrivalled 24,000 industry professionals visiting some 1,500 exhibiting companies from over 125 countries. CPhI is the leading exhibition on pharmaceutical ingredients and allied industries. Each year the exhibition grows larger with exhibitors and visitors conducting significant levels of business at CPhI. Two sister events, ICSE and P-MEC now run alongside CPhI, a tripartite of events that is considered the must attend event for any individual or organisation within the pharmaceutical manufacturing community. In 2001 CPhI was launched in China. ICSE China was launched in 2005 and P-MEC China in 2006.

    For more information, please contact:

     Chris Lee
     Sinovac Biotech Ltd.
     Tel:   +86-10-8279-9659
     Fax:   +86-10-6296-6910
     Email: info@sinovac.com

    Investors:
     Amy Glynn/Stephanie Carrington
     The Ruth Group
     Tel:   +1-646-536-7023/7017
     Email: aglynn@theruthgroup.com
            scarrington@theruthgroup.com

    Media:
     Jason Rando
     The Ruth Group
     Tel:   +1-646-536-7025
     Email: jrando@theruthgroup.com


'/>"/>
SOURCE Sinovac Biotech Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Sinovac to Present at 2010 UBS Global Specialty Pharmaceuticals Conference
2. Sinovac Reports Unaudited First Quarter 2010 Financial Results
3. Sinovac to Host Conference Call to Report First Quarter 2010 Financial Results
4. Sinovac Announces Upsizing and Pricing of Common Share Offering
5. Sinovac Files Clinical Trial Application with SFDA for Vaccine Against Hand, Foot, and Mouth Disease
6. Sinovacs CEO Weidong Yin Presented with Annual Innovation Award by China Central Television
7. Sinovac Establishes Joint Venture to Expand Human-Use Vaccine Development and Manufacturing Capabilities
8. Sinovac Reports Unaudited Third Quarter 2009 Financial Results
9. Sinovac Obtains Third H1N1 Vaccine Order from Chinese Central Government
10. Sinovac Receives Certificate of Approval to Distribute Panflu (H5N1) Vaccine in Hong Kong
11. Sinovac to Present at 2009 UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... 2016 , ... Parallel 6 , the leading software as a service ... Virtual Patient Encounter CONSULT module which enables both audio and video telemedicine communication ... , Using the CONSULT module, patients and physicians can schedule a face to face ...
(Date:6/24/2016)...  Regular discussions on a range of subjects including policies, ... entities said Poloz. Speaking at a lecture to ... he pointed to the country,s inflation target, which is set ... "In certain areas there needs ... economic goals, why not sit down and address strategy together?" ...
(Date:6/23/2016)... ... 23, 2016 , ... UAS LifeSciences, one of the leading ... UP4™ Probiotics, into Target stores nationwide. The company, which has been manufacturing high ... its list of well-respected retailers. This list includes such fine stores as Whole ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, ... microbial test has received AOAC Research Institute approval 061601. , “This is another ... year,” stated Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel ...
Breaking Biology Technology:
(Date:6/15/2016)... New York , June 15, 2016 /PRNewswire/ ... a new market report titled "Gesture Recognition Market by ... and Forecast, 2016 - 2024". According to the report, ... USD 11.60 billion in 2015 and is estimated ... reach USD 48.56 billion by 2024.  ...
(Date:6/2/2016)... -- The Department of Transport Management (DOTM) of ... US Dollar project, for the , Supply and ... and IT Infrastructure , to Decatur ... of Identity Management Solutions. Numerous renowned international vendors participated in ... was selected for the most compliant and innovative solution. ...
(Date:5/20/2016)... , May 20, 2016  VoiceIt is excited ... with VoicePass. By working together, VoiceIt ...  Because VoiceIt and VoicePass take slightly different approaches ... increases both security and usability. ... about this new partnership. "This marketing ...
Breaking Biology News(10 mins):